Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. Issue 7 (October 2021)

• Record Type: Journal Article
• Authors: Baig, Muhammad U.; Rytting, Michael; Roth, Michael; Morani, Ajaykumar C.; Nunez, Cesar; Lin, Pei; Cuglievan, Branko
• Is Part Of: Journal of pediatric hematology/oncology. Volume 43:Issue 7(2021)
• Publication Date: 2021-10
• Subjects: venetoclax -- decitabine -- lymphoblastic lymphoma -- BCL-2 inhibitor; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002050
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Background: Overall survival of adolescents with relapsed T-cell lymphoblastic lymphoma (T-LL) remains poor with limited options for salvage therapy. The BCL-2 inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia. Observation: We present the case of a 19-year-old adolescent with stage III relapsed and refractory T-LL who did not respond to 3 lines of salvage therapy. The patient was treated with venetoclax and decitabine and achieved a dramatic response. Conclusion: This case highlights the potential clinical activity of venetoclax and decitabine in relapsed T-LL.